Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia.

OBJECTIVE: To describe the features of ETV6::ABL1 AML as well as the clinical treatment and outcomes. METHODS: Clinical data were collected from three patients diagnosed with ETV6::ABL1 AML at Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital. Their clinical and laboratory features were analyzed, and the treatment process and outcomes were described. Ten reported cases of ETV6::ABL1 AML from the literature were also included for analysis. RESULTS: The median age of the patients was 34 years, and 2 patients were male. No patient had a history of blood disorders before diagnosis. After relapse, they were referred to our hospital, where the ETV6::ABL1 gene was detected. Unfortunately, Patient 1 died rapidly after leukemia relapse due to severe infection. Patients 2 and 3 received salvage therapy with a dasatinib-containing regimen, followed by allo-HSCT, and are currently alive and disease-free. CONCLUSION: ETV6::ABL1 is a rare but recurrent genetic aberration in AML, and the combined use of fluorescence in situ hybridization and PCR can better identify this fusion gene. Patients carrying ETV6::ABL1 have a high relapse rate and a poor prognosis. TKIs are a reasonable treatment option for this group, and allo-HSCT may be curative.

Ultrasensitive levofloxacin electrochemical biosensor based on semiconducting covalent organic framework/poly-L-cysteine/triangular Ag nanoplates modified glassy carbon electrode.

A novel electrochemical biosensor with excellent performance was fabricated for levofloxacin (LEV) detection, which adopted triangular Ag nanoplates (Tri-AgNP) confined in a poly-L-cysteine (poly-L-Cys) film and a semiconducting covalent organic framework (COF) as the electrochemical sensing material. The developed electrochemical sensor revealed excellent analytical properties because of its good electrical conductivity, fast electron transfer, and abundant bioactive site. Based on this, a linear relationship between the LEV concentration and the peak current response at 0.92 V was obtained under the optimal experimental conditions by differential pulse voltammetry (DPV), with a wide linear range of 0.05 to 600 µM and a low limit of detection (LOD) of 0.0061 µM. The prepared sensor also realized sensitive and accurate determination of LEV in human serum and urine samples by standard addition method, with satisfactory recoveries (97.1 to 104%) and a low relative standard deviation of less than 4.6%. These results indicated that the novel ternary system has a promising application in the development of electrochemical signal probe and electrochemical biosensing platform.

The Efficacy and Safety of Plasma Exchange in the Treatment of Thrombotic Thrombocytopenic Purpura.

Background: Thrombotic thrombocytopenic purpura (TTP) is a clinically rare thrombotic cardiovascular and microvascular disease. The purpose of this study was to observe the clinical efficacy and safety of plasma exchange in the treatment of TTP. Methods: A total of 16 TTP patients who underwent plasma exchange from January 2015 to December 2020 were selected. The clinical data of all patients were collected for retrospective analysis. The effective rate of treatment, the changes of blood cell count before and after treatment, and adverse reactions during treatment were analyzed. Results: A total of 50 plasma exchanges were performed in 16 TTP patients. After plasma exchange treatment, there were 4 invalid and 12 improved patients. The total effective rate of plasma exchange in patients with TTP was 75.0%. After treatment, platelet count (PLT) and hemoglobin (Hb) levels were significantly increased in TTP patients. Compared with before treatment, lactate dehydrogenase (LDH), indirect bilirubin (IBIL), total bilirubin (TBIL), and broken red blood cells were significantly reduced. In addition, 3 adverse reactions occurred in 50 plasmapheresis procedures, and the incidence of adverse reactions was 6.0%. Conclusion: Plasma exchange therapy has a good therapeutic effect on TTP and can significantly improve abnormal blood cell count in patients with high safety.

A ratiometric sensor for selective detection of Hg2+ ions by combining second-order scattering and fluorescence signals of MIL-68(In)-NH2.

Ratio fluorescence has attracted much attention because of its self-calibration properties. However, it is difficult to obtain suitable fluorescent materials with well-resolved signals simultaneously under one excitation. In this work, we report a different strategy, using MIL-68(In)-NH2 as both the fluorescence element and the scattered light unit, and coupling the fluorescence and the scattered light to construct the fluorescence and scattered light ratio system. Based on the optical properties and the second-order scattering (SOS) of the material nanoparticles, the synthesized MIL-68(In)-NH2 can be used to realize the ratio detection of Hg2+. Because the scattering intensity of small particle MIL-68(In)-NH2 is weak, SOS is not obvious. When Hg2+ is introduced the coordination reaction between the amino nitrogen atoms of MIL-68(In)-NH2 and Hg2+ make the particles larger, resulting in the decrease of fluorescence and the enhancement of SOS. As a result, a novel Hg2+ ratiometric detection method is developed by using the dual signal responses of the fluorescence and scattering. Under the optimal conditions (pH = 6, reaction time 5 min, room temperature, and the maximum excitation wavelength 365 nm), the linear range of the method is 0-100 µM, and the detection limit is 5.8 nM (Ksv = 9.89 × 109 M-1). In addition, the probe is successfully used to evaluate Hg2+ in actual water samples. Compared with the traditional method of recording only the fluorescence signal, the proposed fluorescence-scattering method provides a new strategy for the design of ratiometric sensors.